Checkpoints inhibitors in Metastatic Papillary Renal Cell Carcinoma

Papillary Renal Cell Carcinoma (pRCC) is the second most common RCC subtype and accounts for up 15% of all RCC1,2. Historically, pRCC has been associated with adverse outcomes compared to more common clear-cell tumors (ccRCC), mainly when metastatic, consistent with their categorization in non-clear cell RCC (nccRCC) encompassing aggressive and rare RCC subtypes3 –5. The International mRCC Database Consortium (IMDC) prognostic model was effective in stratifying patients with mpRCC, like patients with mccRCC, into favorable-, intermediate-, and poor-risk outcomes6,7.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research